|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chávarri-Guerra Y, Villarreal-Garza C,
Liedke PE, et al: Breast cancer in Mexico: a growing challenge to
health and the health system. Lancet Oncol. 13:e335–e343.
2012.PubMed/NCBI
|
|
3
|
Rodríguez-Cuevas SA and Capurso-García M:
Epidemiology of breast cancer. Ginecol Obstet Mex. 74:585–593.
2006.(In Spanish).
|
|
4
|
Zentella-Dehesa A, Frías S,
Galicia-Vázquez G, et al: Cáncer de glándula mamaria y metástasis:
un creciente problema de salud pública en México. Mensaje
Bioquímico. Oria Hernández J, Rendón Huerta E, Reyes Vivas H,
Romero Álvarez I and Velázquez López I: Mexico: UNAM; XXXI. pp.
172–195. 2007
|
|
5
|
Spallarossa P, Altieri P, Aloi C, et al:
Doxorubicin induces senescence or apoptosis in rat neonatal
cardiomyocytes by regulating the expression levels of the telomere
binding factors 1 and 2. Am J Physiol Heart Circ Physiol.
297:H2169–H2181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Elliott P: Pathogenesis of cardiotoxicity
induced by anthracyclines. Semin Oncol. 33:S2–S7. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rice J: Metastasis: The rude awakening.
Nature. 485:S55–S57. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khuder SA and Mutgi AB: Breast cancer and
NSAID use: a meta-analysis. Br J Cancer. 84:1188–1192. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Agrawal A and Fentiman IS: NSAIDs and
breast cancer: a possible prevention and treatment strategy. Int J
Clin Pract. 62:444–449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson TW, Anderson KE, Lazovich D and
Folsom AR: Association of aspirin and nonsteroidal
anti-inflammatory drugs use with breast cancer. Cancer Epidemiol
Biomarkers Prev. 11:1586–1592. 2002.PubMed/NCBI
|
|
11
|
Harris RE, Chlebowski RT, Jackson RD, et
al: Breast cancer and nonsteroidal anti-inflammatory drugs:
prospective results from the Women’s Health Initiative. Cancer Res.
63:6096–6101. 2003.
|
|
12
|
Ratnasinghe LD, Graubard BI, Kahle L,
Tangrea JA, Taylor PR and Hawk E: Aspirin use and mortality from
cancer in a prospective cohort study. Anticancer Res. 24:3177–3184.
2004.PubMed/NCBI
|
|
13
|
Marshall SF, Bernstein L, Anton-Culver H,
et al: Nonsteroidal anti-inflammatory drugs use and breast cancer
risk by stage and hormone receptor status. J Natl Cancer Inst.
97:805–812. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Egan KM, Stampfer MJ, Giovannucci E,
Rosner BA and Colditz GA: Prospective study of regular aspirin use
and the risk of breast cancer. J Natl Cancer Inst. 88:988–993.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kirsh VA, Kreiger N, Cotterchio M, Sloan M
and Theis B: Nonsteroidal anti-inflammatory drug use and breast
cancer risk: subgroup findings. Am J Epidemiol. 166:709–716. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Terry MB, Gammon MD, Zhang FF, et al:
Association of frequency and duration of aspirin use and hormone
receptor status with breast cancer risk. JAMA. 291:2433–2440. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Coogan PF, Palmer JR, Strom BL
and Rosenberg L: Use of nonsteroidal anti-inflammatory drugs and
risk of breast cancer: the case-control surveillance study
revisited. Am J Epidemiol. 162:165–170. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Friis S, Sørensen HT, McLaughlin JK,
Johnsen SP, Blot WJ and Olsen JH: A population-based cohort study
of the risk of colorectal and other cancers among users of low-dose
aspirin. Br J Cancer. 88:684–688. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Friis S, Thomassen L, Sørensen HT, et al:
Nonsteroidal anti-inflammatory drug use and breast cancer risk: a
Danish cohort study. Eur J Cancer Prev. 17:88–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cook NR, Lee IM, Gaziano JM, et al:
Low-dose aspirin in the primary prevention of cancer. The Women’s
Health Study: a randomized controlled trial. JAMA. 294:47–55.
2005.
|
|
21
|
Jacobs EJ, Thun MJ, Connell CJ, et al:
Aspirin and other nonsteroidal anti-inflammatory drugs and breast
cancer incidence in a large U.S. cohort. Cancer Epidem Biomarkers
Prev. 14:261–264. 2005.PubMed/NCBI
|
|
22
|
Jacobs EJ, Thun MJ, Bain EB, Rodriguez C,
Henley SJ and Calle EE: A large cohort study of long-term daily use
of adult strength aspirin and cancer incidence. J Nat Cancer Inst.
99:608–615. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schreinemachers DM and Everson RB: Aspirin
use and lung, colon, and breast cancer incidence in a prospective
study. Epidemiology. 5:138–146. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bardia A, Ebbert JO, Vierkant RB, et al:
Association of aspirin and non-aspirin non-steroidal
anti-inflammatory drugs with cancer incidence and mortality. J Natl
Cancer Inst. 99:881–889. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Badawi AF, Habib SL, Mohammed MA, Abadi AA
and Michael MS: Influence of cigarette smoking on prostaglandin
synthesis and cyclooxygenase-2 gene expression in human urinary
bladder cancer. Cancer Invest. 20:651–656. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martey CA, Pollock SJ, Turner CK, et al:
Cigarette smoke induces cyclooxygenase-2 and microsomal
prostaglandin E2 synthase in human lung fibroblast: implications
for lung inflammation and cancer. Am J Physiol Lung Cell Mol
Physiol. 287:L981–L991. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ready A, Velicer CM, McTiernan A and White
E: NSAID use and breast cancer risk in the VITAL cohort. Breast
Cancer Res Treat. 109:533–543. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gill JK, Maskarinec G, Wilkens LR, Pike
MC, Henderson BE and Kolonel LN: Nonsteroidal anti-inflammatory
drugs and breast cancer risk: the multiethnic cohort. Am J
Epidemol. 166:1150–1158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Langman MJS, Cheng KK, Gilman EA and
Lancashire RJ: Effect of anti-inflammatory drugs overall risk of
common cancer: case-control study in general practice research
database. BMJ. 320:1642–1646. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moorman PG, Grubber JM, Millikan RC and
Newman B: Association between nonsteroidal anti-inflammatory drugs
(NSAIDs) and invasive breast cancer and carcinoma in situ of the
breast. Cancer Causes Control. 14:915–922. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cotterchio M, Kreiger N, Sloan M and
Steingart A: Nonsteroidal anti-inflammatory drug used and breast
cancer risk. Cancer Epidemiol Biormarkers Prev. 10:1213–1217.
2001.PubMed/NCBI
|
|
32
|
García Rodríguez LA and González Pérez A:
Risk of breast cancer among users of aspirin and other
anti-inflammatory drugs. Br J Cancer. 91:525–529. 2004.PubMed/NCBI
|
|
33
|
Swede H, Mirand AL, Menezes RJ and Moysich
KB: Association of regular aspirin use and breast cancer risk.
Oncology. 68:40–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Slattery ML, Curtin K, Baumgartner R, et
al: IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast
cancer risk in women living in the southwestern United States.
Cancer Epidemiol Biomarkers Prev. 16:747–755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hojo T, Akiyama Y, Nagasaki K, et al:
Association of maspin expression with the malignancy grade and
tumor vascularization in breast cancer tissues. Cancer Lett.
171:103–110. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maass N, Hojo T, Rosel F, Ikeda T, Jonat W
and Nagasaki K: Down regulation of the tumor suppressor gene maspin
in breast carcinoma is associated with a higher risk of distant
metastasis. Clin Biochem. 34:303–307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Girish GV, Sinha N, Chakraborty K,
Bhattacharya G, Kahn NN and Sinha AK: Restoration by aspirin of
impaired plasma maspin level in human breast cancer. Acta Oncol.
45:184–187. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bhattacharyya M, Girish GV, Ghosh R,
Chakraborty S and Sinha AK: Acetylsalicylic acid (aspirin) improves
synthesis of maspin and lowers incidence of metastasis in breast
cancer patients. Cancer Sci. 101:2105–2109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rothwell PM, Wilson M, Price JF, Belch JF,
Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer
metastasis: a study of incident cancers during randomised
controlled trials. Lancet. 379:1592–1601. 2012.PubMed/NCBI
|
|
40
|
Bambace NM and Holmes CE: The platelet
contribution to cancer progression. J Thromb Haemostat. 9:237–249.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nature Rev Cancer.
9:239–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gay LJ and Felding-Habermann B:
Contribution of platelets to tumour metastasis. Nature Rev Cancer.
11:123–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Holmes MD, Chen WY, Li L, Hetzmark E,
Spiegelman D and Hankinson SE: Aspirin intake and survival after
breast cancer. J Clin Oncol. 28:1467–1472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Smith WL, DeWitt DL and Garavito RM:
Cyclooxygenases: structural, cellular, and molecular biology. Annu
Rev Biochem. 69:145–182. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zha S, Yegnasubramanian V, Nelson WG,
Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: progress and
perspective. Cancer Lett. 215:1–20. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Giercksky KE: COX-2 inhibition and
prevention of cancer. Best Pract Res Clin Gastroenterol.
15:821–833. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ulrich CM, Bigler J and Potter JD:
Non-steroidal anti-inflammatory drugs for cancer prevention:
promise, perils and pharmacogenetics. Nature Review Cancer.
6:130–140. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Moran EM: Epidemiological and clinical
aspects of nonsteroidal anti-inflammatory drugs and cancer risk. J
Environ Pathol Toxicol Oncol. 21:193–202. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vane JR and Botting RM: Mechanism of
action of aspirin-like drugs. Semin Arthritis Rheum. 26:2–10. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Buttar NS and Wang KK: The “aspirin” of
the new millenium: cyclooxigenase-2 inhibitors. Mayo Clin Proc.
75:1027–1038. 2000.
|
|
51
|
Elwood PC, Gallagher AM, Duthie GG, Mur LA
and Morgan G: Aspirin, salicylates, and cancer. Lancet.
373:1301–1309. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Langley RE, Burdett S, Tierney JF,
Cafferty F, Parmar MK and Venning G: Aspirin and cancer: has
aspirin been overlooked as an adjuvant therapy? Br J Cancer.
105:1107–1113. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Meric JB, Rottey S, Olaussen K, Soria JC,
Khayat D, Rixe O and Spano JP: Cyclooygenase-2 as a target for
anticancer drug development. Crit Rev Oncol Hematol. 59:51–64.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hwang D, Scollard D, Byrne J and Levine E:
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast
cancer. J Natl Cancer Inst. 90:455–460. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
He TC, Chan TA, Volgestein B and Kinzlet
KW: PPAR delta is an APC-regulated target of nonsteroidal
anti-inflammatory drugs. Cell. 99:335–345. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Davies G, Martin LA, Sacks N and Dowsett
M: Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a
possible role for COX-2 inhibitors in breast cancer
chemoprevention. Ann Oncol. 13:669–678. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Subbaramaiah K, Chung WJ and Dannenberg
AJ: Ceramide regulates the transcription of cyclooxygenase-2.
Evidence for involvement of extracellular signal-regulated
kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein
kinase pathways. J Biol Chem. 273:32943–32949. 1998. View Article : Google Scholar
|
|
58
|
Brueggemeier RW, Quinn AL, Parrett ML,
Joarder FS, Harris RE and Robertson FM: Correlation of aromatase
and cyclooxygenase gene expression in human breast cancer
specimens. Cancer Lett. 140:27–35. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Goss PE, Ingle JN, Martino S, et al: A
randomized trial of letrozole in postmenopausal women after five
years of tamoxifen therapy for early breast cancer. N Engl J Med.
349:1793–1802. 2003.PubMed/NCBI
|
|
60
|
Mazhar E, Ang R and Waxman J: COX
inhibitors and breast cancer. Br J Cancer. 94:346–350. 2006.
View Article : Google Scholar
|
|
61
|
Bosetti C, Gallus S and La Vecchia C:
Aspirin and cancer risk: an updated quantitative review to 2005.
Cancer Causes Control. 17:871–888. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Crew KD and Neugut AI: Aspirin and NSAIDs:
effects in breast and ovarian cancers. Curr Opin Obstet Gynecol.
18:71–75. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Fosslien E: Molecular pathology of
cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 30:3–21.
2000.PubMed/NCBI
|
|
64
|
Bosetti C, Gallus S and La Vecchia C:
Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev.
11:535–542. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Howe LR, Subbaramaiah K, Brown AMC and
Dannenberg AJ: Cyclooxygenase-2: a target for the prevention and
treatment of breast cancer. Endocr Relat Cancer. 8:97–114. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ratnasinghe D, Daschner PJ, Anver MR, et
al: Cyclooxygenase-2 P-glycoprotein-170 and drug resistance; is
chemoprevention against multidrug resistance possible? Anticancer
Res. 21:2141–2147. 2001.PubMed/NCBI
|
|
67
|
Streuli CH: Maspin is a tumour suppressor
that inhibits breast cancer tumour metastasis in vivo. Breast
Cancer Res. 4:137–140. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
68
|
Solomon LA, Munkarah AR, Schimp VL, et al:
Maspin expression and localization impact on angiogenesis and
prognosis in ovarian cancer. Gynecol Oncol. 101:385–389. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Burnett GT, Weathersby DC, Taylor TE and
Bremner TA: Regulation of inflammation and angiogenesis-related
gene expression in breast cancer cells and co-cultured macrophages.
Anticancer Res. 28:2093–2099. 2008.PubMed/NCBI
|
|
70
|
Spitz GA, Furtado CM, Sola-Penna M and
Zancan P: Acetylsalicylic acid and salicylic acid decrease tumor
cell viability and glucose metabolism modulating
6-phosphofructo-1-kinase structure and activity. Biochem Pharmacol.
77:46–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
